首页 | 本学科首页   官方微博 | 高级检索  
文章检索
  按 检索   检索词:      
出版年份:   被引次数:   他引次数: 提示:输入*表示无穷大
  收费全文   1335432篇
  免费   100213篇
  国内免费   4273篇
耳鼻咽喉   16812篇
儿科学   43584篇
妇产科学   36358篇
基础医学   197845篇
口腔科学   35939篇
临床医学   129571篇
内科学   258117篇
皮肤病学   26382篇
神经病学   111861篇
特种医学   48174篇
外国民族医学   366篇
外科学   184087篇
综合类   28772篇
现状与发展   1篇
一般理论   460篇
预防医学   114410篇
眼科学   28982篇
药学   98832篇
  6篇
中国医学   3167篇
肿瘤学   76192篇
  2021年   10905篇
  2019年   11635篇
  2018年   16318篇
  2017年   12287篇
  2016年   13247篇
  2015年   15193篇
  2014年   20799篇
  2013年   32052篇
  2012年   44240篇
  2011年   46892篇
  2010年   27077篇
  2009年   24925篇
  2008年   42711篇
  2007年   45058篇
  2006年   45169篇
  2005年   43599篇
  2004年   41566篇
  2003年   39504篇
  2002年   38321篇
  2001年   60862篇
  2000年   62525篇
  1999年   52289篇
  1998年   14586篇
  1997年   13281篇
  1996年   13117篇
  1995年   12458篇
  1994年   11629篇
  1993年   10925篇
  1992年   41573篇
  1991年   40765篇
  1990年   39458篇
  1989年   37345篇
  1988年   34582篇
  1987年   33699篇
  1986年   32159篇
  1985年   30641篇
  1984年   23036篇
  1983年   19590篇
  1982年   11753篇
  1979年   20811篇
  1978年   14819篇
  1977年   12068篇
  1976年   11878篇
  1975年   12116篇
  1974年   14805篇
  1973年   14475篇
  1972年   13360篇
  1971年   12420篇
  1970年   11487篇
  1969年   10411篇
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
111.
112.
Elderly men with clinical and laboratory evidence of androgen deficiency are eligible for testosterone treatment.

With proper monitoring this is acceptably safe.

In the first year of testosterone treatment there should be a digital rectal examination of the prostate and measurement of prostate specific antigen every three months, thereafter yearly.

The rate of increase of prostate specific antigen (PSA) levels is more significant than its absolute values.

Levels of haemoglobin and the haematocrit should be monitored.  相似文献   

113.
Atherosclerotic renal artery stenosis (ARAS) may cause hypertension, progressive renal failure, and recurrent pulmonary edema. It typically occurs in high risk patients with coexistent vascular disease elsewhere. Most patients with ARAS are likely to die from coronary heart disease or stroke before end-stage renal failure occurs. Recent controlled trials have shown that most patients undergoing angioplasty to treat renovascular hypertension still need antihypertensive agents 6 or 12 months after the procedure. Nevertheless, the number of antihypertensive agents required to control blood pressure adequately is lower following angioplasty than for medication alone. Trials assessing the value of revascularization for preserving renal function or preventing clinical events are only in the early recruitment phase. Revascularization should be undertaken in patients with ARAS and resistant hypertension or heart failure, and probably in those with rapidly deteriorating renal function or with an increase in plasma creatinine levels during angiotensin-converting enzyme inhibition. With or without revascularization, medical therapy using antihypertensive, hypolipidemic and antiplatelet agents is necessary in almost all cases.  相似文献   
114.
115.
116.
117.
Interferon-alpha (IFN-alpha) has proved effective in the treatment of hemangiomas, hemangioblastomas, and Kaposi's sarcoma. To investigate the ability of IFNs to inhibit angiosarcoma, we used two transformed murine endothelial cell lines that form angiosarcomas in vivo. SVR and MS1-VEGF cell lines express oncogenic H-ras or vascular endothelial growth factor (VEGF), respectively. IFN-alpha1,8, which is active against murine and human cells, inhibited SVR and MS1-VEGF proliferation in vitro by 40% at 10(3) U/mL (p = 0.028). In vivo, IFN-alpha1,8 inhibited SVR tumor volume by 71% (p = 0.047) and MS1-VEGF volume by 79% (p = 0.003). Tumor-induced angiogenesis was decreased in SVR tumors by 52% (p = 0.005) and in MS1-VEGF tumors by 58% (p = 0.001). Sera from IFN-alpha1,8-treated mice bearing either SVR or MS1-VEGF tumors demonstrated a 5-fold increase in IP-10/CXCL10 (p = 0.001), an IFN-induced antiangiogenic protein. Both recombinant IP-10 and IFN-alpha1,8 inhibited human umbilical vein endothelial cell (HUVEC) vessel formation in the fibrin gel assay, a three-dimensional culture model of angiogenesis, by 56% at 25 ng/mL and 50% at 1.2 ng/mL, respectively (p < 0.001). An IP-10 blocking antibody restored vessel formation to 80% of untreated controls (p = 0.001). Given the magnitude of the in vivo response, these data suggested that the antitumor effects of IFN-alpha1,8 were likely mediated through angiogenesis inhibition rather than solely by direct inhibition of tumor cell proliferation.  相似文献   
118.
Relationship-centered care reflects both knowing and feeling: the knowledge that physician and patient bring from their respective domains of expertise, and the physician’s and patient’s experience, expression, and perception of emotions during the medical encounter. These processes are conveyed and reciprocated in the care process through verbal and nonverbal communication. We suggest that the emotional context of care is especially related to nonverbal communication and that emotion-related communication skills, including sending and receiving nonverbal messages and emotional self-awareness, are critical elements of high-quality care. Although nonverbal behavior has received far less study than other care processes, the current review argues that it holds significance for the therapeutic relationship and influences important outcomes including satisfaction, adherence, and clinical outcomes of care.  相似文献   
119.
A 19-item survey instrument was designed and mailed by the Infectious Diseases Society of America to its membership to determine the media preferred by infectious diseases physicians for continuing medical education on general topics and on antimicrobial resistance. The objective of the survey was to offer the developers of educational programs knowledge on which to base more-effective ways to deliver educational materials to physicians in this specialty.  相似文献   
120.
Knowing Ron     
Spechko  Phyllis L. 《JAMA》2006,296(7):738
  相似文献   
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号